 |
|
Phospho(Ser473)/Total Akt Base Kit
|
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin, J.J., Edgar, K.A., Guan, J., Berry, M., Prior, W.W., Lee, L., Lesnick, J.D., Lewis, C., Nonomiya, J., Pang, J., Salphati, L., Olivero, A.G., Sutherlin, D.P., O'Brien, C., Spoerke, J.M., Patel, S., Lensun, L., Kassees, R., Ross, L., Lackner, M.R., Sampath, D., Belvin, M., Friedman, L.S.
|
Mol Cancer Ther. |
2011 |
|
Osteopontin Is Required for the Early Onset of High Fat Diet-Induced Insulin Resistance in Mice.
Chapman, J., Miles, P.D., Ofrecio, J.M., Neels, J.G., Yu, J.G., Resnik, J.L., Wilkes, J., Talukdar, S., Thapar, D., Johnson, K., Sears, D.D.
|
PLoS ONE |
2010 |
|
Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells.
Grund, E.M., Kagan, D., Tran, C.A., Zeitvogel, A., Starzinski-Powitz, A., Nataraja, S., Palmer, S.S.
|
Mol Pharmacol. |
2008 |
|
Development of sulfonamide AKT PH domain inhibitors.
Ahad, A.M., Zuohe, S., Du-Cuny, L., Moses, S.A., Zhou, L.L., Zhang, S., Powis, G., Meuillet, E.J., Mash, E.A.
|
Bioorg Med Chem Lett |
2011 |
|
Efficacy of Ganitumab (AMG 479), Alone and in Combination With Rapamycin, in Ewing's and Osteogenic Sarcoma Models.
Beltran, P.J., Chung, Y.A., Moody, G., Mitchell, P., Cajulis, E., Vonderfecht, S., Kendall, R., Radinsky, R., Calzone, F.J.
|
Pharmacol Exp Ther. |
2011 |
|
|
|
|
 |
| Price |
Please call for price |
| Size |
20 plates |
| Catalog No. |
K15100A-3 |
| Availability |
Usually ships in 1-3 days |
|
Home
Products
K15100A-3
